Iohexol

碘海醇

Report date: 2026/03/24 20:00:35
NME

Base Information

Drug NameIohexol
Drug Alias NameIohexolum碘酯六醇三碘三酰苯碘笨六醇碘苯六醇 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNonionic monomeric iodinated radiographic contrast agents
TargetsNot applicable
Therapy Area/IndicationsContrast agentsContrast-induced nephropathyFabry Disease +[7] 
Global Approved IndicationsContrast agents
Approved Indications in ChinaContrast agents
Original Approved Country/TerritoryUnited States
Original Approved Date1985/12/26
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGe Healthcare
China Registration ClassN/A

Develop Information

Active CompaniesGe HealthcareYangtze River Pharmaceutical (Group) Co Ltd
Inactive CompaniesCydex Pharmaceuticals IncLigand Pharmaceuticals IncColumbia University +[5] 
Active IndicationsContrast agents
Inactive IndicationsContrast-induced nephropathyFabry DiseaseNeoplasm Metastasis +[6] 

Other Information

ATC CodeV08AB02
Related LinksWikipediaDrugBankKEGG